BioMedNewsBreaks

ThursdayMay 16, 2024 1:56 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period…

Continue Reading

ThursdayMay 16, 2024 1:33 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Releases Q1 2024 Financial Results

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced its financial results for the first quarter ended March 31, 2024. During the quarter, the company’s revenue reached $1.0 million, an 8% increase compared to the fourth quarter of 2023, underscoring HealthLynked’s resilience and adaptability in managing transitions while maintaining operational efficiency. The announcement noted HealthLynked’s continued strategic focus on cost control, which saw the company reduce operating expenses in the Health Services Division by 33%, SG&A expenses by 9%, and overall operating expenses by 22% in Q1 2024 compared to Q1 2023. The company reported a net loss from…

Continue Reading

ThursdayMay 16, 2024 1:18 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on the board. An Estonian citizen, Glinka has served in several executive and board roles positions in large European companies, including Automecanica Skb Property Srl., GST Investments OU and TG Biochemicals Ltd. Glinka’s expertise will support and facilitate new licensing and networking opportunities for Nutriband throughout Europe as the company works to expand its AVERSA(TM) technology, which is patented in 45 countries. The announcement noted that…

Continue Reading

ThursdayMay 16, 2024 1:02 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting its full-year financial results for 2023 along with a company update. Highlights of the report included news that, in the first four months of 2024, the company has received CDMO work orders valued at approximately $500,000, with current guidance for this year of approximately $1.25 million in expected revenues. The report also noted that the company is “aggressively advancing” its NanoAb preclinical development, with promising results obtained in a…

Continue Reading

WednesdayMay 15, 2024 3:35 pm

BioMedNewsBreaks — Why HealthLynked Corp. (HLYK) Is ‘One to Watch’

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, is revolutionizing patient care through innovative digital solutions. “With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries,” a recent article reads. “In addition to these capabilities,…

Continue Reading

WednesdayMay 15, 2024 3:27 pm

BioMedNewsBreaks — Astiva Health Reshaping Personalized and Comprehensive Healthcare Landscape

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, has always been working on improving its provider network and physician-patient relationships, ensuring health plans align with client needs and directives. “It is this [physician-patient] partnership that Astiva is implementing in its groundbreaking approach to creating a dynamic and innovative Medicare Advantage Prescription Drug (‘MAPD’) health plan designed to reshape the landscape of personalized and comprehensive healthcare. Astiva Health provides access to experienced and dedicated providers who work together with its members to pave a pathway toward better health,” a recent article…

Continue Reading

WednesdayMay 15, 2024 1:54 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Announces Q1 2024 Financial Results

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the comparable period in 2023. Sigyn Therapeutics’ net loss for Q1 2024 was $758,088 or $0.62 per share, as compared to a net loss of $1,341,036, or $1.39 per share, during Q1 2023. During the first quarter, SIGY completed a 1-for-40 reverse split of its common stock. As a result, 1,224,827 shares of company’s common stock are currently…

Continue Reading

WednesdayMay 15, 2024 1:37 pm

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL) Announces Record Consolidated Q1 2024 Revenues, Improved Quarterly Margins

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced record financial results for the first fiscal quarter ended March 31, 2024, which includes the consolidation of the operations of its e-commerce business with the results of its healthcare operations, Progressive Care Inc. (OTCQB: RXMD). “First quarter results continued to demonstrate the fundamental strength of NextPlat’s focus on the large healthcare services and global e-commerce technology markets and further demonstrates our team execution against its global growth plans,” said Charles M. Fernandez, executive chairman and CEO of NextPlat Corp. “Throughout the remainder of 2024, we are committed to maximizing and…

Continue Reading

WednesdayMay 15, 2024 1:28 pm

BioMedNewsBreaks — PaxMedica Inc. (PXMD) Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting

  PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has filed a formal notice of appeal with the NASDAQ Office of Appeals and Review; the company is appealing to reverse the decision of the NASDAQ Hearings Panel to delist the company from. The company also announced that it has retained Jacob Frenkel, Dickinson Wright, PLLC as its lead counsel in the appeal. According to the announcement, PaxMedica believes the hearings panel did not sufficiently or appropriately consider crucial aspects of the company’s recent achievements and ongoing actions to regain compliance. “We are seeking a reevaluation…

Continue Reading

WednesdayMay 15, 2024 8:30 am

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Releases Q2 Financial Report

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, has filed on its second-quarter 2024 financial results for the period ending March 31, 2024; the company filed the report with the U.S. Securities and Exchange Commission on May 14, 2024. Notable numbers from the report include cash and cash equivalent totaling $3.51 million, with additional agreements adding approximately $2.5 million more in available cash with property, equipment and intangible assets reported at approximately $7.92 million. The report also noted that the company has a clinical asset in NV-387 that is available for partnering, which could result in a…

Continue Reading